Patient Deaths in China Trials Spur U.S. Demand for FDA Scrutiny
1. [para. 1][para. 2][para. 3] U.S. lawmakers are urging the Food and Drug Administration to closely scrutinize clinical-trial data from China after three patient deaths in Chinese gene-editing and cell-therapy studies were disclosed. In an Aug. 20 letter, Representatives John Moolenaar and Ben Cline pressed Acting FDA Commissioner Kyle A. Diamantas to tighten oversight, arguing the U.S. regulatory system cannot rely on data generated in opaque, high-risk environments. The deaths only came to light through foreign media reports beginning in late July.
2. [para. 4][para. 5][para. 6][para. 7][para. 8][para. 9] The three fatalities occurred in China-based investigator-initiated trials (IITs), which are launched by medical institutions to explore scientific principles and are overseen by health authorities rather than strict drug regulators. Two of the deaths involved children undergoing gene editing: one child with Snijders Blok-Campeau syndrome died of thrombotic microangiopathy linked to the viral vector, in a study funded by the patient’s parents; another child with Duchenne muscular dystrophy died of acute respiratory distress syndrome in a study backed by HuidaGene Therapeutics. The third fatality was a middle-aged man with scleroderma in an in vivo CAR-T study funded by RiboX Therapeutics. Under Chinese rules at the time, such deaths did not have to be publicly disclosed, only reported to ethics committees and regulators.
3. [para. 10][para. 11][para. 12][para. 13] The lawmakers’ letter highlighted this lack of basic transparency, saying the scale of unreported deaths and serious adverse events in China’s clinical-trial system remains unknown. They called on the FDA to reject Chinese clinical-trial data for U.S. investigational new drug applications, new drug applications, and biologics license applications unless the agency had conducted an on-site inspection of the trial facility within the preceding 12 months. They also demanded a comprehensive risk assessment of U.S. reliance on Chinese data, especially in high-risk fields like gene editing.
4. [para. 14][para. 15][para. 16][para. 17] According to the U.S. Government Accountability Office, the FDA conducted 46 clinical-trial site inspections in China between 2012 and March 1, 2023. The new scrutiny marks a sharp reversal of the previous U.S. view of China’s IIT framework as a model of speed and efficiency. Former FDA Commissioner Marty Makary has noted that China begins four times as many Phase 1 clinical trials as the U.S., calling it a competitive threat, while the FDA’s fiscal year 2027 budget report proposed a Clinical Trial Notification Pathway modeled in part on China’s IIT system.
5. [para. 18][para. 19][para. 20][para. 21] However, the letter overlooks a recent regulatory overhaul in China. The three deaths occurred before May 1, when Beijing introduced sweeping new rules for clinical research in emerging biomedical technologies. IITs involving cell therapy, gene editing, and brain-computer interfaces now require strict filing procedures, public information disclosure, and heavy penalties for noncompliance. Industry insiders say the requirements are so stringent that most advanced IITs have been halted; thousands of projects await approval, and among 93 registered studies so far, none involve gene editing.
6. [para. 22][para. 23][para. 24] U.S. pushback is not limited to IITs. Scrutiny is expanding to investigational new drug applications sponsored by pharmaceutical companies for commercial approval. In May, the U.S. House Appropriations Committee approved a nonbinding draft report that would prohibit the FDA from accepting clinical-trial data generated in China, Russia, Iran, or North Korea. The measure passed the House in June and is awaiting Senate consideration.
7. [para. 25][para. 26][para. 27] The legislative efforts reflect broader anxieties over China’s growing role in drug development. Many U.S. pharmaceutical companies now use Chinese clinical-trial data or acquire assets from Chinese biotech firms to cut costs and speed timelines. China’s out-licensing deals for innovative drugs reached roughly $110 billion across 81 transactions in the first half of 2026, about 80% of the previous year’s total and a new record. Lan Gongtao, deputy director of China’s National Medical Products Administration, said China accounts for about 30% of all new drugs in development globally, ranking second worldwide.
AI generated, for reference only